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There have been many attempts in cancer clinical-type classiﬁcation by using a dataset from a number of
molecular layers of biological system. Despite these efforts, however, it still remains difﬁcult to elucidate
the cancer phenotypes because the cancer genome is neither simple nor independent but rather compli-
cated and dysregulated by multiple molecular mechanisms. Recently, heterogeneous types of data, gen-
erated from all molecular levels of ‘omic’ dimensions from genome to phenome, for instance, copy number
variants at the genome level, DNA methylation at the epigenome level, and gene expression and microRNA
at the transcriptome level, have become available. In this paper, we propose an integrated framework
that uses multi-level genomic data for prediction of clinical outcomes in brain cancer (glioblastoma mul-
tiforme, GBM) and ovarian cancer (serous cystadenocarcinoma, OV). From empirical comparison results
on individual genomic data, we provide some preliminary insights about which level of data is more
informative to a given clinical-type classiﬁcation problem and justify these perceptions with the corre-
sponding biological implications for each type of cancer. For GBM, all clinical outcomes had a better
the area under the curve (AUC) of receiver operating characteristic when integrating multi-layers of
genomic data, 0.876 for survival to 0.832 for recurrence. Moreover, the better AUCs were achieved from
the integration approach for all clinical outcomes in OV as well, ranging from 0.787 to 0.893. We found
that the opportunity for success in prediction of clinical outcomes in cancer was increased when the pre-
diction was based on the integration of multi-layers of genomic data. This study is expecting to improve
comprehension of the molecular pathogenesis and underlying biology of both cancer types.
 2012 Elsevier Inc. All rights reserved.1. Introduction
An understanding of the molecular basis of cancer brings many
beneﬁts for predicting clinical outcomes of cancer and for deter-
mining the corresponding best treatment. Since cancer is related
to alterations in the genes that control normal cell growth and
death, molecular-based diagnostics are promising in that they
may provide more opportunities for objective, precise, and system-
atic predictions on cancer. Data at the multiple molecular levels,
generated from all levels of ‘omic’ dimensions from genome to
phenome (Fig. 1), have recently becomemore available. At the gen-
ome level, copy number variants have attracted considerable
attentions, since alterations of genomic DNA can be explored by
expanding the scope of view to a larger region of the genome orll rights reserved.
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.to chromosomes. At the epigenome level, data from DNA methyla-
tion, which plays a crucial role in the control of gene activity, is of
interest, while at the level of the transcriptome, gene expression
and microRNA (miRNA) are the most representative datasets.
DNA microarrays have already been widely used for the classiﬁca-
tion of tumor subtypes or clinical outcomes for the diagnosis, treat-
ment, or prognosis of cancer for many years [3,13,15,19,34,47].
More recently, miRNA has become available for understanding
the inhibition of expression on target mRNAs in gene regulatory
networks.
There have been attempts at cancer classiﬁcation using a set of
miRNA, copy number alterations (CNAs), and DNA methylation
[4,6,27,30,51]. Despite these efforts, however, it still remains difﬁ-
cult to elucidate the cancer phenotypes because the cancer genome
is neither simple nor independent but rather complicated and dys-
regulated by multiple molecular mechanisms [9,18]. For example,
the cancer genome is related tomutations in coding and non-coding
sequences, changes in the DNA structure and copy number, DNA
methylation andhistonemodiﬁcation, andmiRNA regulation. Those
possibilities lead to many alternative forms of cause-and-result in
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Fig. 1. Multi-layers of genomic data in biological system from genome, epigenome, transcriptome and proteom to phenome. There are many exceptional variations within or
between levels: copy number variant (CNV), sequence mutation, and genomic rearrangement in genome level; DNA methylation and histone modiﬁcation in epigenome
level; alternative splicing and miRNA regulation in transcriptome level; post translational modiﬁcation in proteom level. Multiple graphs given from different genomic levels
are integrated into one by ﬁnding an optimum value of the linear combination coefﬁcient ak for the individual graph. TF, transcription factor; TFbs, transcription factor
binding site; Me, methylation.
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eventually, gene and protein functions (Fig. 1). Thus, no single level
of genomic data will be sufﬁcient to comprise all of the information
in themechanism, and hence, a consideration of the layered process
of biological systems through incorporation of multiple levels of
genomic data will provide a much more reasonable prediction of
cancer phenotypes.
The Cancer Genome Atlas (TCGA) is a collaborative initiative to
improve understanding of cancer using existing large-scale whole-
genome technologies. The TCGA research network lately published
two notable papers on glioblastoma patients concerning an interim
analysis of DNA sequencing, copy number, gene expression, and
DNA methylation data [45], and discovery of links between cancer
subtypes and different neural lineages with gene expression [48].
While the TCGA opens many opportunities to researchers to dee-
pen the knowledge of the molecular basis of cancer [16,24], it is
particularly important to access multiple data sources as we pro-
pose here.
In this paper, we propose an integrated framework that uses
multi-level genomic data sources for the molecular-based classiﬁ-
cation of clinical outcomes in brain cancer (glioblastoma multi-
forme; GBM) and ovarian cancer (serous cystadenocarcinoma;
OV). GBM is the most common and aggressive primary brain tumor
in adults [14], and notorious for its tendency to recur [37]. Despite
recent advances in the molecular pathology of GBM, the underlingmolecular mechanisms associated with clinical outcome are still
poorly understood [14,38]. OV is one of the most common gyneco-
logical malignancies, and is the 5th leading cause of cancer mortal-
ity in women in the United States [21]. Understanding the
molecular pathogenesis and underlying biology for both types of
cancer is expected to provide guidance for improved prognostic
indicators and effective therapies.
In computational biology, this work will be a pioneering at-
tempt to predict the cancer phenotype based on the underlying
complex biological mechanisms. From individual TCGA data
sources, we conducted empirical comparisons at each level of
genomic data; to deduce possible biological implications based
on the results of the relative contribution of each piece of data to
increase prediction accuracy. We show that accuracy of prediction
increases because of incorporation of information fused over heter-
ogeneous biological data sources, providing an enhanced global
view on cancer mechanisms.
Several approaches to multiple data integration have been ap-
plied to protein function prediction such as the kernel-based inte-
gration framework [2,22,33], the Relevance Vector Machine (RVM)
approach [52], and a Bayesian model [20]. In recent years, we
developed an integration method of protein networks based on
graph-based semi supervised learning (SSL) [41,46]. SSL is a half-
way method between unsupervised learning and supervised learn-
ing, which takes an advantage of both unlabeled data and labeled
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matical background, model visualization, sparseness properties as
well as the close relationship with kernel methods. In terms of
integration issues, learning with other methods such as support
vector machine (SVM) and Markov random ﬁeld (MRF) may not
be ﬁnished in a reasonable time when the data is large-scale, e.g.
TCGA dataset (Appendix A). Although, any of the above mentioned
methods could be used to implement the proposed idea, the graph-
based SSL is employed in this study, taking advantage of computa-
tional efﬁciency and representational ease for the biological sys-
tem. The learning time of graph-based SSL is nearly linear with
the number of graph edges, which in most biological networks is
few, while the accuracy remains comparable to the kernel-based
methods that suffer from the relative disadvantage of a longer
learning time [42,46]. In addition, the interpretation of biological
phenomena can be improved because of the graph data structure
[31,40,44], which naturally ﬁts into the graph based SSL.
There have been several studies for integrative analysis of differ-
ent levels of genomic data such as pairs of ‘CNA-gene expression’
[7,29,39], ‘miRNA-gene expression’ [23,32,50], and ‘methylation-
gene expression’ [12,25]. These approaches are generally based on
regression or correlation analysis, which ﬁt into combining two
levels of genomic data and are not designed to accommodate an-
other level of genomic data. Thus, these methods have a difﬁculty
to integrate more than three types of genomic data because of
non-scalability. On the other hand, many integrative approaches
have been proposed to combine more than three types of genomic
data through the gene-based integration; that is, heterogeneous
genomic data from different sources were analyzed sequentially,
then each genomic data mapped into the gene level for the integra-
tion [26,35,36]. However, information loss might occur by such
gene-based integration from the different levels of genomic data
because there is no guarantee to be a simple one-to-one relation-
ship between each feature of multi-layers of genomic data and a
speciﬁc gene such as relations of exon-gene, miRNA-gene, CNA-
gene, and methylation-gene. Therefore, here we propose a data
integration framework for different levels of genomic data, not only
with a scalable formalism to extend another level of genomic data
but preserving level-speciﬁc properties from the multi-layers and
heterogeneous genomic data.
The manuscript is organized as follows. Data description and
methods for graph-based SSL and the integration approach are ex-
plained in Section 2. In Section 3, experimental results in GBM and
OV are provided to demonstrate the validity and effectiveness of
our integrative approach. Finally, we discuss the meaning of our
study and future works in the last section.
2. Materials and methods
2.1. Data
Datasets were retrieved from the TCGA data portal (http://
www.tcga-data.nci.nih.gov/) (Supplementary Table 2). Table 1Table 1
Data description.
Cancer type Data type Platform
GBM CNA Agilent Huma
Methylation Illumina DNA
Gene expression Affymetrix H
miRNA Agilent 8  1
OV CNA Agilent SureP
Methylation Inﬁnium hum
Gene expression Affymetrix H
miRNA Agilent Humashows the data description of the multi-level genomic datasets in
GBM and OV. CNA belongs to the genome level, methylation to
the epigenome level, gene expression and miRNA to the level of
the transcriptome. The fourth column shows the number of fea-
tures for each type of genomic data. Five sets of binary classiﬁca-
tion problems were set using the phenotype information from
patients depending on the types of clinical outcomes (Table 2).
Using the clinical outcome from GBM, the two sets of problems
are deﬁned: (1) short-term or long-term survival and (2) initial or
recurrent tumor. In the classiﬁcation of short-term or long-term sur-
vival, ‘short-term’ represents the samples from patients who sur-
vived less than 9 months, whereas ‘long-term’ means samples
derived from patients who survived longer than 24 months [28].
In the classiﬁcation of initial or recurrent tumor, ‘initial tumor’
indicates samples from surgical resections with no pretreatment
history, while samples from secondary surgeries for tumor recur-
rence are deﬁned as ‘recurrent tumor.’ Similarly, the remaining
three sets of classiﬁcations are deﬁned using OV clinical outcomes,
which are as follows: (3) early stage (T1–T2) or late stage (T3–T4),
(4) low grade (G1–G2) or high grade (G3–G4), and (5) short-term
(<3 y) or long-term (P3 y) survival [5]. The last column of Table 2
summarizes the number of available (positive/negative) samples
for each of these problems.2.2. Clinical outcome classiﬁcation
We used a graph-based semi-supervised learning as a classiﬁca-
tion algorithm, which is a halfway learning scheme between super-
vised and unsupervised learning [1,8,53,54]. If two patients’
samples were more closely related than to others, we assumed that
the clinical outcomes of those two patients were more likely to be
similar. In other words, clinical outcome prediction can be done
by considering relationships between patient samples. A natural
method of analyzing relationships between samples is a graph,
where nodes depict patient samples and edges represent their pos-
sible relations. Fig. 2 presents a cartoon graph of patient samples. An
annotated sample is labeled either by ‘1’ or ‘1’, indicating the two
possible clinical outcomes, either ‘normal’ or ‘cancer’. To predict the
label of the unannotated sample ‘?’, the edges connected from/to the
sample play an important role in inﬂuencing propagation between
the sample and its neighbors. This idea can be easily formulated
using graph-based SSL [53]. Edges represent relations, more
speciﬁcally similarities between samples that may be extracted
from different genomic sources of CNA, methylation, gene expres-
sion, miRNA, etc. Different data sources produce different graphs.
Clinical outcome prediction can beneﬁt by integrating diverse
graphs from diverse genomic data sources, rather than relying only
on single sources that may have possible limitations, (i.e. incom-
plete information and noise). When data sources are presented as
a graph form, combining multiple data sources can be done by
employing a graph integration method [41,42,46].# Features (d)
n Genome CGH Microarray 244A 235,829
Methylation OMA003 Cancer Panel 1 1498
T Human Genome U133 Array Plate Set 12,043
5 K Human miRNA-speciﬁc microarray 534
rint G3 Human CGH Microarray Kit 1  1 M 962,434
anmethylation27 BeadChip 27,578
T Human Genome U133 Array Plate Set 12,043
n miRNA Microarray Rel12.0 799
Table 2
Clinical outcomes.
Cancer
type
Clinical outcome # Samples (n)a
(Neg/Pos)
GBM Short-term survival (survived less than 9 months)
vs. long-term survival (survived longer than
24 months)
82 (54/28)
Initial tumor (initial diagnosis) vs. recurrent
tumor (tumor recurrence)
159 (39/120)
OV Short-term survival (survived less than 3 years)
vs. long-term survival (survived longer than
3 years)
348 (150/198)
Early stage (T1 or T2) vs. late stage (T3 or T4) 503 (39/464)
Low grade (G1 or G2) vs. high grade (G3 or G4) 496 (65/431)
a Solid tumor samples from each type of cancer were only considered.
Fig. 2. A graph model of relationships between patient samples. Nodes represent
patient samples and edges depict relations between samples. An annotated sample
is labeled either by 1 or +1. In this example, the negative labels indicate samples
from ‘normal’ patients. On the contrary, the positive labels indicate the samples
from ‘cancer’ patients. The clinical outcome of the unannotated sample marked as
‘?’ is predicted by employing graph-based semi-supervised learning.
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In the graph-based SSL algorithm [53], a sample xi (i = 1, . . .,n) is
represented as a node i in a graph, and the relationship between
samples is represented by an edge. The edge strength from each
node j to each other node i is encoded in element wij of a n  n
symmetric weight matrix W. A Gaussian function of Euclidean dis-
tance between samples, with length scale hyperparameter r, is
used to specify connection strength2:
wij ¼ exp 
ðxixjÞT ðxixjÞ
r2
 
if i  j;
0 otherwise:
8<
: ð1Þ
Nodes i, j are connected by an edge if i is in j’s k-nearest-neighbor-
hood or vice versa. Therefore, nearby samples in Euclidean spaces
are assigned large edge weights. The labeled nodes have labels yl -
2 {1,1}, while the unlabeled nodes have zeros yu = 0. SSL will out-
put an n-dimensional real-valued vector f ¼ ½f Tl f Tu T ¼
ðf1; . . . ; fl; flþ1; . . . ; fn¼lþuÞT , which can be thresholded to make label
predictions on fl=1, . . ., fn after learning. We require (a) the score fi
should not be too different from the scores of adjacent vertices,
and (b) the scores should be close to the given label yi in training
nodes. One can obtain f by minimizing the following quadratic func-
tional [1,8,53]:
Xl
i¼1ðfi  yiÞ
2 þ c
Xn
i¼lþ1f
2
i þ l
Xn
i;j¼1wijðfi  fjÞ
2 ð2Þ2 xi and xj are d-dimensional column vector and ()T means the transpose of ().The ﬁrst term corresponds to the loss function in terms of condition
(b), and the third term describes the smoothness of the scores in
terms of condition (a). The parameter l trades off loss vs. smooth-
ness. The second term is a regularization term to keep the scores of
unlabeled nodes in a reasonable range. Alternative choices of
smoothness and loss functions can be found in Chapelle et al. [8].
From later on, we focus on the special case c = 1 [53]. Then, the
three terms reduce to the following two terms in matrix notation,
min
f
ðf  yÞTðf  yÞ þ lf TLf ð3Þ
where y = (y1, . . .,yl, 0, . . ., 0)T, and the matrix L, called the graph
Laplacian matrix [10], is deﬁned as L = D W where D = diag(di),
di =
P
jwij. The parameter l trades off loss vs. smoothness. The solu-
tion of this problem is obtained as
f ¼ ðI þ lLÞ1y ð4Þ
where I is the identity matrix.
2.3. Integration of multi-level genomic data sources
From multi-level genomic data sources, multiple graphs are
generated. Information from each graph is regarded as partially
independent from and partly complementary to others. Therefore,
it is not accurate enough to elucidate phenotype using only a single
genomic data source belonging to a speciﬁc single layer. Reliability
may be enhanced by integrating all available information sources
using the method proposed by Tsuda et al. [46] and Shin and Tsuda
[42], which has been re-validated on the extended problem of pro-
tein function prediction [41]. According to the method, the integra-
tion of multiple graphs is used to ﬁnd an optimum value of the
linear combination coefﬁcient for the individual graphs. This corre-
sponds to ﬁnding the combination coefﬁcients a for the individual
Laplacians of the following mathematical formulation:
min
a
yT I þ
XK
k¼1akLk
 1
y;
X
k
ak 6 l ð5Þ
where K is the number of graphs (data sources) and Lk is the corre-
sponding graph-Laplacian of graph Gk. One can perceive the formu-
lation by synchronizing the schematic descriptions shown in Fig. 1.
Similar to the output prediction for single graphs, the solution is ob-
tained by
f ¼ I þ
XK
k¼1akLk
 1
y ð6Þ3. Results
From the multi-levels of genomic data available from TCGA, the
following ﬁve sets of clinical outcome classiﬁcations were deﬁned:
for GBM, (1) short-term or long-term survival and (2) initial or
recurrent tumor and for OV (3) early or late stage; (4) low or high
grade; (5) short-term or long-term survival. For the ﬁve sets of bin-
ary classiﬁcation problems, the proposed approach, prediction from
integration of multi-level genomic data sources, was compared with
the four individual predictions obtained from CNA, methylation,
gene expression, and miRNA. For each problem, we calculated
the area under the curve (AUC) of receiver operating characteristic
(ROC) [17] and the true positive rate yielding an 1% false positive
rate (TP1FP) as performance measurements [22]. The dataset was
randomly splited so that 80% of the samples are assigned to the
training set and 20% to the validation set to ﬁnd the model param-
eters. The overall performance was measured through three times
of ﬁvefold cross validation. The Wilcoxon signed-rank test was
used to validate the signiﬁcance of the difference in performance
for all the combinations of the comparisons [11]. Details on the
Table 3
AUC results on GBM clinical outcomes.
Clinical outcome Data type AUC (p-valuea) TP1FP
Short-term survival vs.
long-term survival
CNA 0.8160 (2.19e26) 0.30
Methylation 0.7408 (1.19e28) 0.60
Gene expression 0.8560 (1.22e11) 0.72
miRNA 0.7480 (1.07e28) 0.40
Multi-level data 0.8760 0.80
Initial tumor vs.
recurrent tumor
CNA 0.8131 (3.04e04) 0.65
Methylation 0.6774 (3.30e33) 0.20
Gene expression 0.6667 (2.09e34) 0.15
miRNA 0.7226 (1.15e33) 0.43
Multi-level data 0.8369 0.75
a The p-value of the pairwise Wilcoxon signed-rank test in AUCs between the
multi-level integration approach and the single data approaches.
D. Kim et al. / Journal of Biomedical Informatics 45 (2012) 1191–1198 1195model parameter selection are available in Supplementary
methods.3.1. Glioblastoma multiforme
Table 3 shows the AUC performance on the two sets of classiﬁ-
cations of GBM clinical outcomes. The AUCs of the four individual
sources (CNA, methylation, gene expression, and miRNA) are
shown in the ﬁrst four rows and the AUC of the proposed ap-
proach—integration with multi-level genomic data sources is shown
in the ﬁfth row. For the short-term survival vs. long-term survival
classiﬁcation, the SSL with gene expression data performed best
with 0.8560 AUC (underlined) among the four genomic data
sources, and CNA data showed comparable performance with an
AUC of 0.8160. However, none of the AUC values from single data
sources could outperform the AUC of 0.8760 (boldface) generated
by the multi-level genomic data. The p-values of the pairwise com-
parisons in AUC between the proposed approach and the single
data approaches demonstrate that a statistically signiﬁcant differ-
ence exists in performance. The superior performance of the inte-
gration approach is also found in terms of the value of the
TP1FP—of 0.8, the highest among the ﬁve. Furthermore, for the ini-
tial tumor vs. recurrent tumor classiﬁcation, the SSL with CNA data
showed the best performance with an AUC value of 0.8131 (under-
lined) among the four individual data sources, but again the perfor-
mance of the integration approach was superior to that of the best
individual approach with an AUC of 0.8369 and TP1FP of 0.75
(boldface) was superior to all of the individual approaches.Table 4
AUC results on OV clinical outcomes.
Clinical outcome Data type AUC (p-valuea) TP1FP
Short-term survival vs.
long-term survival
CNA 0.6547 (1.24e28) 0.17
Methylation 0.7251 (1.34e27) 0.14
Gene expression 0.7651 (8.96e10) 0.26
miRNA 0.6403 (1.24e28) 0.17
Multi-level data 0.7867 0.40
Early stage vs. late stage CNA 0.8767 (1.87e05) 0.74
Methylation 0.7149 (1.51e28) 0.61
Gene expression 0.8332 (2.31e05) 0.53
miRNA 0.7661 (1.39e21) 0.78
Multi-level data 0.8932 0.80
Low grade vs. high grade CNA 0.8014 (3.43e05) 0.37
Methylation 0.8161 (4.63e09) 0.57
Gene expression 0.7676 (2.59e06) 0.39
miRNA 0.6887 (9.61e15) 0.16
Multi-level data 0.8678 0.54
a The p-value of the pairwise Wilcoxon signed-rank test in AUCs between the
multi-level integration approach and the single data approaches.3.2. Serous cystadenocarcinoma
Table 4 shows the AUC performance of the three sets of classi-
ﬁcation problems of OV clinical outcomes. For the short-term sur-
vival vs. long-term survival classiﬁcation, the SSL with gene
expression data performed best with an AUC of 0.7651 when com-
pared with the other single genomic data sources. Note that a sim-
ilar result was obtained for GBM, which might imply that the
information from gene expression data plays a critical role in the
classiﬁcation of short-term vs. long-term survival. Among the four
individual sources, the best performing data differed for each clas-
siﬁcation; for the early stage vs. late stage classiﬁcation, the predic-
tion from CNA data showed the best performance (0.8767 AUC)
while for the low grade vs. high grade classiﬁcation, methylation
data performed best (0.8161 AUC). However, the AUC of the pro-
posed approach consistently outperforms the individual best for
all of the three sets of problems, attaining values of 0.7867,
0.8932, and 0.8678. There is a slight degradation of the proposed
approach in TP1FP for the low grade vs. high grade classiﬁcation,
but the magnitude in difference is negligible (0.57 in methylation
data vs. 0.54 in multi-level integrated data).
3.3. Integration effect
We found that the integration of various genomic data sources
increases the performance of clinical outcome prediction. As a next
step, we investigated the effect of integration by considering all
possible combinations of the four multi-level genomic data
sources. Fig. 3 shows a gradual increase in AUC by integration:
for the short-term survival vs. long-term survival classiﬁcation of
GBM (Fig. 3A) and for the low grade vs. high grade classiﬁcation
of OV (Fig. 3B), where C stands for CNA, M for methylation, E for
gene expression, and R for miRNA, and the combinations are repre-
sented as MR, CMR, and so on. AUC consistently increases as more
data sources are added to the combination in both GBM and OV. In
Fig. 3A, for instance, AUC increases in the order of mass of combi-
nations, C < CR < CMR < CMER. These ﬁndings suggest that biologi-
cal information may be fused to various data sources from different
genomic levels; therefore, integration of those independent or
complementary pieces of information may elevate the opportunity
of success in prediction of clinical outcomes in cancer.
3.4. Biological implication
On the basis of the results of our computational experiments,
some biological and clinical implications may be cautiously drawn.
Fig. 4 illustrates the following observations that show the level of
contributions of multi-level genomic data sources for the ﬁve clas-
siﬁcation problems. As of yet, there has been no clear-cut deﬁnition
on boundaries between the different genomic levels; but, it is nat-
urally conceived that the structural changes in the chromosome or
chromatin will lead to the changes on data sources obtained from
the genome or the epigenome level (CNA and methylation in our
experiment) before the inﬂuence reaches to the transcriptome le-
vel. On the other hand, the functional changes caused by the by-
products of DNA will be more directly related to the changes on
data sources generated from the transcriptome level (mRNA and
miRNA in our experiment).
First, the CNA data performed best in the initial vs. recurrent tu-
mor classiﬁcation in GBM and the early vs. late stage classiﬁcation
in OV. Both problems concern the structural changes in chromo-
some by the elapsed amount of time since tumor initiation
[43,49]. Therefore CNA data might have provided appropriate
information for classifying the alternative clinical outcomes.
Second, the performance of the gene expression data was supe-
rior to those of others in the short-term vs. long-term survival
(A) GBM: short-term survival vs. long-term survival
(B) OV: low grade vs. high grade
Fig. 3. Gradual increase in AUC by integration: C stands for CNA, M for methylation, E for gene expression, and R for miRNA, and the combinations are represented as MR,
CMR, and so on. (A) The short-term vs. long-term survival classiﬁcation of GBM. (B) The low vs. high grade classiﬁcation of OV.
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malignant behavior of the tumor is related to the functional
changes of genes or proteins [3] which can be detected by gene
expression data in our experimental setting. Interestingly, the gene
expression data performed as good as the other three dataset
(CMR), and almost as good as the full dataset (CMER) (Fig. 3A). This
calls for additional bioinformatical analyses. One intriguing
possibility suggests that the same genomic loci contribute clinical
information in more than one domain – the same genes that
change in their copy number and methylation patterns also pres-
ent predictive powers based on mRNA expression levels.
Third, the methylation data performed best for the low vs. high
grade classiﬁcation of OV. Despite the lack of understanding of epi-
genomic characteristics in cancer, we suggest that structural
changes may be worthy of further study.Fourth, even though we made an ad hoc separation on genomic
data to structural changes or functional changes, the phenotype of
clinical outcome is not inﬂuenced by only one of them. As shown in
Fig. 4, the integration of all genomic data sources can be helpful to
unveil the relationship from genome to phenome.4. Discussion
Since cancer is the phenotypic end-point of events cumulated
through multiple levels of the biological system from genome to
proteome, a single layer of biological information will not be sufﬁ-
cient to fully understand tumor behavior or the underlying biolog-
ical mechanisms [18]. In the present study, a pilot framework of
integration of multiple levels of genomic data sources, CNA, DNA
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Late stage
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High grade
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Fig. 4. Performance comparison of genomic data over the ﬁve sets of clinical outcome classiﬁcation problem: C stands for CNA, M for methylation, E for gene expression, R for
miRNA, and I for the integration of the four data sources, which corresponds to CMER of Fig. 3.
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plied to the problem of prediction of clinical outcomes in GBM and
OV.
When comparing individual genomic data sources, we sug-
gested some preliminary insights that medical experts or biologists
may consider. The main result of our study is that integration of
multi-layers of genomic data sources increases the opportunity
of success in prediction of clinical outcomes in cancer. To the best
of our knowledge, this study is the ﬁrst effort in molecular-based
classiﬁcation of clinical outcomes from cancer patients, by unfold-
ing and integrating the genomic, the epigenomic, and the tran-
scriptomic features in their samples. In addition, the proposed
framework would be easily extended when novel genomic data
from different levels is available.
This study underpins our on-going work. There are possible
relationships between the sample features (attributes) belonging
to different layers of genomic data such as ‘miRNA-target genes,’
‘copy number alteration region-genes located in the alteration re-
gion,’ and ‘DNA methylation site-speciﬁc genes regulated by pro-
moter regions.’ Therefore, when integrating multiple genomic
data, it will be desirable that a framework will be capable of con-
taining the inter-relationships between sample features belonging
to different layers of the biological system.
Recently, there has been an announcement from TCGA that
additional cancer genomic data for about 20–25 tumor types will
be generated in the next few years as the second phase of the
project. With abundance in multi-layers of genomic and clinical
data, our proposed integrative framework will be valuable for elu-
cidating the underlying tumor behavior, eventually leading to
more effective screening strategies and therapeutic targets in
many types of cancer. The Matlab code will be available upon
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